Moderna, Inc. (MRNA)
| Market Cap | 9.67B |
| Revenue (ttm) | 2.23B |
| Net Income (ttm) | -3.12B |
| Shares Out | 390.73M |
| EPS (ttm) | -8.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,713,200 |
| Open | 24.21 |
| Previous Close | 24.15 |
| Day's Range | 23.99 - 24.80 |
| 52-Week Range | 22.28 - 48.92 |
| Beta | 1.11 |
| Analysts | Hold |
| Price Target | 33.91 (+37.01%) |
| Earnings Date | Nov 6, 2025 |
About MRNA
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]
Financial Performance
In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for MRNA stock is "Hold." The 12-month stock price target is $33.91, which is an increase of 37.01% from the latest price.
News
Moderna, Inc. (MRNA) Analyst/Investor Day Transcript
Moderna, Inc. ( MRNA) Analyst/Investor Day November 20, 2025 9:00 AM EST Company Participants Stéphane Bancel - CEO & Director Stephen Hoge - President Jerh Collins - Chief Technical Operations & Qua...
Moderna takes $1.5 billion loan, expects 10% revenue growth next year
Moderna said on Thursday it secured a five-year loan of $1.5 billion from Ares Management , as it targets up to 10% revenue growth next year.
Moderna Secures $1.5 Billion Five-Year Credit Facility from Ares Management
Non-dilutive financing from premier lender bolsters strong balance sheet and provides increased flexibility Company reiterates 2025 financial guidance provided on 3Q25 earnings call and targets cash b...
Moderna Analyst Day Highlights Pipeline Progress and Business Strategy Updates
Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 Expects to expand seasonal vaccine franchise from three to up to six approved products ...
Moderna to complete US mRNA manufacturing network with $140 million investment
Moderna said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a major step in strengthening the company's domestic production network.
Moderna Expands U.S. Manufacturing with Onshoring of Drug Product Capabilities
New capabilities strengthen U.S. production, completing Moderna's domestic end-to-end mRNA manufacturing network More than $140 million investment will create hundreds of highly skilled biomanufacturi...
Moderna to Present at Upcoming Piper Sandler's 37th Annual Healthcare Conference on December 2, 2025
CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / November 18, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference: Piper Sandler's 37th Annu...
What Is Going On With Moderna Stock?
Moderna (MRNA) stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return. The company's value has increased by approximately $1.2 billion over th...
Telemark Asset Management Builds Position in Beaten-Down Biotech Stock.
Initiated stake: 500,000 shares, an estimated $12.91 million increase Post-trade Moderna position: 500,000 shares, valued at $12.91 million Moderna now accounts for 1.23% of Telemark's reportable AUM,...
Moderna, Inc. (MRNA) Q3 2025 Earnings Call Transcript
Moderna, Inc. ( MRNA) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Lavina Talukdar - Senior VP & Head of Investor Relations Stéphane Bancel - CEO & Director James Mock - Ch...
mRNA Vaccine Maker Moderna Lowers R&D Spending, Tightens Sales Forecast
Moderna Inc. (NASDAQ:MRNA) reported a third-quarter loss of 51 cents, beating the expected loss of $2.02, a turnaround from an income of 3 cents a year ago.
Moderna trims top end of full-year forecast on weak COVID vaccine sales
Moderna lowered the top end of its 2025 revenue forecast by $200 million on Thursday, citing weaker-than-expected sales of its COVID-19 vaccine in the U.S. as Americans struggled to access the shots.
Moderna Swings to a Loss on Fewer Covid-19 Vaccine Sales
Moderna swung to a loss and logged lower sales in the third quarter as it works to expand its offerings amid weakening demand for its Covid-19 vaccine.
Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates
Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected revenue range to $1.6 - $2.0 billion Improves 2025 expected GAAP operating...
Moderna Stock Is Sliding Monday: What's Going On?
Moderna Inc (NASDAQ:MRNA) stock is trading sharply lower on Monday afternoon as recent clinical setbacks overshadowed positive pipeline news.
Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma
CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the Company's investigational ...
Moderna: Focus On Cancer Vaccines, Not Buyout
Moderna surged on reports of talks with a large biopharma for a potential partnership or buyout, despite trading at multi-year lows. MRNA's promising cancer vaccine data and surprising findings on mRN...
Moderna (MRNA) Stock Is Trading Lower Friday: What's Going On?
Moderna Inc (NASDAQ:MRNA) shares are trading lower on Friday afternoon, giving back a portion of the gains seen on Thursday. Here's what investors need to know.
S&P 500 Gains and Losses Today: Meta Stock Drops After Earnings; Moderna Surges
Shares of a social media juggernaut slumped as investors balked at its rapidly accelerating spending on artificial intelligence, while reports of potential partnership or buyout talks helped a vaccine...
Moderna Named a Top Employer by Science for Eleventh Consecutive Year
CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers...
Moderna Stops CMV Program As Vaccine Falls Short In Preventing Infection
Moderna, Inc. (NASDAQ:MRNA) revealed topline results on Wednesday from a Phase 3 trial evaluating the efficacy of mRNA-1647, the company's investigational cytomegalovirus (CMV) vaccine. CMV is a herpe...
Moderna to Host Investor Event - Analyst Day
CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its Investor Event - Analyst Day at 9:00 a.m. ET on Thursday, November 20, 2025.
Moderna ends development of CMV vaccine after trial failure
Moderna said on Wednesday it will discontinue development of its experimental vaccine to prevent cytomegalovirus, a common cause of birth defects, after it failed to meet the main goal of a late-stage...
Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint
Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patients Company does not anticipate an...
Prediction: Moderna Will Soar Over the Next 5 Years. Here's 1 Reason Why.
Moderna's shares have been southbound for the past few years due to unimpressive financial results. However, progress with the pipeline could significantly boost the stock over the next five years.